Company / Gross Profit
Lineage Cell Therapeutics, Inc. Gross Profit History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$8.3M
FY2023
5-year range
$1.4M / $8.3M
FY2019-FY2023
Trend
+183.8%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Profit has fluctuated over the past 8 years, ranging from $1M in FY2021 to $8M in FY2023.
Based on SEC 10-K filings.
$8M in FY2023 with a 5-year CAGR of +20.3%.
Improved from $1M to $8M over the past 2 years.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +38.7%
- 5-Year CAGR
- +20.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +20.3%, indicating consistent growth.
- In FY2023, gross profit increased 183.8% year-over-year.
- Lowest gross profit in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $8.3M | +183.8% |
| FY2022 | $2.9M | +102.3% |
| FY2021 | $1.4M | -53.6% |
| FY2020 | $3.1M | -33.8% |
| FY2019 | $4.7M | +42.4% |
| FY2018 | $3.3M | -44.5% |
| FY2017 | $5.9M | +34.5% |
| FY2016 | $4.4M | +21.0% |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026